Affluent Partners (HKG:1466) unit Beijing Baijin Biotechnology entered into a strategic cooperation framework agreement with Taihe Huamei (Zhejiang) Medical Technology to develop a new medicine in Mainland China, a Monday bourse filing said.
The new medicine, KMHH-03, which has been developed by Taihe Huamei (Zhejiang) Medical Technology, has obtained preliminary approval from China's National Medical Products Administration and is currently undergoing first-stage clinical research.
Under the contract, Beijing Baijin Biotechnology will invest in Taihe Huamei (Zhejiang) Medical Technology by subscribing for equity interest in the latter.
The parties are yet to decide the time and value of the investment under the contract, which will expire Dec. 31, 2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。